This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Centre National De La Recherche Scientifique. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Robinson Triboulet: Innovator in Retrovirus Treatment
Introduction
Robinson Triboulet is a notable inventor based in Paris, France. He has made significant contributions to the field of medical science, particularly in the treatment of retrovirus infections. His innovative work has the potential to impact the lives of many individuals affected by such infections.
Latest Patents
Robinson Triboulet holds a patent for "Compositions and methods for treating retrovirus infections." This invention relates to at least one nucleic acid that comprises or consists of, or encodes a nucleic acid comprising or consisting of, a sequence selected from a specific group. The sequences include SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4. The invention is particularly aimed at inducing HIV-1 expression in latent HIV-1-infected cells, providing a potential medicament for treating retrovirus infections. He has 1 patent to his name.
Career Highlights
Robinson Triboulet is affiliated with the Centre National de la Recherche Scientifique, a prestigious research institution in France. His work there has allowed him to focus on groundbreaking research in virology and therapeutic methods.
Collaborations
Throughout his career, Robinson has collaborated with esteemed colleagues such as Bernard Mari and Jacques Reynes. These partnerships have fostered an environment of innovation and have contributed to the advancement of research in retrovirus treatments.
Conclusion
Robinson Triboulet is a dedicated inventor whose work in treating retrovirus infections showcases the importance of innovation in medical science. His contributions are paving the way for new therapeutic approaches that could benefit many patients in need.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
